Bioxytran Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical Trials
BIOXYTRAN, INC. (BIXT) announced successful animal testing results for its Acellular Oxygen Carrier BXT-25, designed to treat COVID-19 and other viral diseases. The treatment showed non-toxicity and full recovery in Swiss Albino mice, even after a significant blood loss. BXT-25 is significantly smaller than a blood cell, allowing it to reach hypoxic areas of the body, potentially revolutionizing treatment for conditions like strokes and neurodegenerative diseases. The company plans to conduct further toxicity studies and aims to submit an Investigational New Drug Application to the FDA for clinical trials on stroke patients. Initial non-clinical studies indicated no toxicity and effective oxygen delivery, bolstering the drug's therapeutic potential.
- BXT-25 demonstrated non-toxicity and full recovery in animal tests.
- Significant therapeutic potential for conditions like strokes and Alzheimer's.
- Plans for further studies and FDA Investigational New Drug Application submission.
- Pending funding may delay further toxicity studies and clinical trials.
BOSTON, MASSACHUSETTS, April 19, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced that its long awaited Acelluar Oxygen Carrier BXT-25 has been successfully tested in animals. The initial results are very encouraging because they show the non-toxicity of the experimental drug, along with the corresponding full recovery in Swiss Albino mice, in an experiment carried out in a joint venture with NDPD Pharma, Inc. As a next step, the Company intends to proceed with a 14-day repeated dose toxicity study using New Zealand Rabbits and Wistar Rats as funding permits.
The animal protocol used on the Swiss Albino mice hemorrhaged
This breakthrough opens up the possibility of creating one of the largest platform drugs in existence. Since BXT-25 is 5,000 times smaller than a blood cell, it has the ability to permeate hypoxic regions of the body’s organs where the vasculature doesn’t support good blood flow. Many familiar with Hyperbaric Oxygen Treatment (HBOT) could think of BXT-25 as the intravenous version of HBOT treatment that lasts 9-18 hours and without any harmful side effects. HBOT treatment typically lasts no more than 1.25 hours daily, due to the risks of side effects. The platform drug was designed to be non-toxic and target both hypoxia and degenerative diseases. The company expects BXT-25 will represent a new paradigm in the way strokes and neurodegenerative diseases such as Alzheimer’s, Dementia, and Traumatic Brain Injury are treated. Other indications like ARDS, Sickle Cell Anemia, and Wound healing are some diverse indications that could benefit from BXT-25. The company also has an exclusive license to use the MDX viewer in clinical trials. The MDX viewer is FDA Approved, with a 510-K label to measure the level of hypoxia in cells.
About BXT-25
BXT-25, will be tested as a potent resuscitative agent to treat cerebrovascular accidents. The product is based on a new molecule reversing hypoxia in areas have limited access, originally developed for cerebral contrast imaging. The company plans to submit an Investigational New Drug Application to the Food and Drug Administration (FDA) and enter into clinical trials on stroke patients.
Initial non-clinical studies on animals indicated positive results:
- No nitric oxide scavenging (absence of increased blood pressure)
- No animal toxicity.
- Oxygen delivery to hypoxic cells
The Company’s objective is to conduct proof of concept clinical trials for safety and efficacy of BXT-25 and enter into business relations with several large drug companies.
About Bioxytran, Inc.
Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, Prolectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. Bioxytran’s other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at www.bioxytraninc.com
Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
Forward-Looking Statements
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
FAQ
What are the results of BXT-25's animal trials?
What conditions could BXT-25 potentially treat?
What is the next step for BXT-25 after animal testing?
How does BXT-25 compare to traditional Hyperbaric Oxygen Treatment?
